TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3677281

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate 1% with epinephrine 1/400,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% with epinephrine 1/400,000
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mepivacaine 1% with epinephrine 1/400,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 29693796

Group type: EXPERIMENTAL
Intervention: Cabozantinib 30 mg/m2/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg/m2/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cabozantinib 55 mg/m2/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cabozantinib (all dose levels)
Number of subjects: 41
Study: 26916566

Group type: EXPERIMENTAL
Intervention: Siponimod 4 mg after 192 hours of discontinuation
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Siponimod (various doses) after up to 96 hours of discontinuation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Siponimod (various doses)
Number of subjects: 138
Study: 25594427

Group type: EXPERIMENTAL
Intervention: CT327 (TrkA inhibitor)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 160
Study: 23099100

Group type: EXPERIMENTAL
Intervention: Computerized decision support tools in the EHR delivered to primary care providers at the point of care
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Computerized decision support tools in the EHR with direct-to-parent support (telephone coaching and twice-weekly text messages)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 800
Study: 20176986

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 6801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6801

Group type: EXPERIMENTAL
Intervention: Statins (meta-analysis)
Number of subjects: 6801
Study: 17522613

Group type: EXPERIMENTAL
Intervention: Lactose-free milk
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ordinary milk
Number of subjects: 33
Study: 16766116

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Tadalafil 10mg
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 12478068

Group type: EXPERIMENTAL
Intervention: HAART plus hydroxyurea (HU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 20
Study: 10861881

Group type: EXPERIMENTAL
Intervention: Breathing pure oxygen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Breathing pure oxygen without breath-hold
Number of subjects: 9

Group type: COMPARATOR
Intervention: Breathing pure oxygen with breath-hold
Number of subjects: 9

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 9
Study: 8677865

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (n = 911; 33%)
Number of subjects: 2723

Group type: COMPARATOR
Intervention: No beta-blocker therapy (n = 1,812; 67%)
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 2723
Study: 1355798

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10(6), 5 x 10(7), 5 x 10(8), 5 x 10(9), or 1 x 10(10) CFU)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10(8) CFU)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10(9) CFU)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo (5 x 10(8) inactivated Escherichia coli K-12)
Number of subjects: 412
Study: 31584677

Group type: EXPERIMENTAL
Intervention: Brief admission to hospital by self-referral
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29742655

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200-3,000 mg/d)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 26912177

Group type: EXPERIMENTAL
Intervention: Skill-building intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% price reductions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention (skill-building + 20% price reductions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skill-building resources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24152706

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) loading (5 g of Cr + 10 g of fructose, four times daily for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (10 g of fructose, four times daily for 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) loading
Number of subjects: 12
Study: 23155026

Group type: EXPERIMENTAL
Intervention: Diet with 2,650 kcal of AME(n)/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Diet with 2,750 kcal of AME(n)/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Diet with 2,850 kcal of AME(n)/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Diet with 2,950 kcal of AME(n)/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Heavier hens (1,733 g)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Lighter hens (1,606 g)
Number of subjects: 130
Study: 20538329

Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diluent inhalation
Number of subjects: 12
Study: 17960305

Group type: EXPERIMENTAL
Intervention: Moderate/Heavy drinking partners
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Social network with drinkers
Number of subjects: 102
Study: 16260701

Group type: EXPERIMENTAL
Intervention: IFNalpha and isotretinoin (206 patients)
Number of subjects: 407

Group type: COMPARATOR
Intervention: IFNalpha and placebo (201 patients)
Number of subjects: 407
Study: 16259830

Group type: EXPERIMENTAL
Intervention: Current users of hormone replacement therapy (HRT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-users of hormone replacement therapy (HRT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 124
Study: 9530793

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Muscle relaxants
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Narcotics
Number of subjects: 219

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 219
Study: 8681495

Group type: EXPERIMENTAL
Intervention: Albendazole (440 mg/two times per day for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albendazole (400 mg/two times per day for 7 days) plus metronidazole (250 mg/three times per day for 7 days)
Number of subjects: 20
Study: 2229783

Group type: EXPERIMENTAL
Intervention: Learning group (n = 84)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Testing group (n = 27)
Number of subjects: 111
Study: 390158

Group type: EXPERIMENTAL
Intervention: Baclofen (GABA analogue)
Number of subjects: 0
Study: 30982748

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) 1 L per day for 28 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 12
Study: 28912958

Group type: EXPERIMENTAL
Intervention: Nurse-delivered mental health intervention (six individual sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study: 26055855

Group type: EXPERIMENTAL
Intervention: Vesicoureteral reflux (VUR)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Bladder and bowel dysfunction (BBD)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Presence of renal scarring on baseline scan
Number of subjects: 500

Group type: COMPARATOR
Intervention: No VUR
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: VUR
Number of subjects: 500
Study: 23926208

Group type: EXPERIMENTAL
Intervention: Nonfasting remnant cholesterol
Number of subjects: 60608

Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 60608
Study: 21878535

Group type: EXPERIMENTAL
Intervention: Letrozole + AS1402 (9 mg/kg weekly infusion)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Letrozole only (2.5 mg daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Letrozole + AS1402
Number of subjects: 110
Study: 19214676

Group type: EXPERIMENTAL
Intervention: HEV antigen positive group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HEV antigen
Number of subjects: 70

Group type: COMPARATOR
Intervention: anti‐HEV IgM positive group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HEV RNA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: anti‐HEV IgM
Number of subjects: 70
Study: 17950094

Group type: EXPERIMENTAL
Intervention: Miglitol 150 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mitiglinide 30 mg/d
Number of subjects: 28
Study: 17147758

Group type: EXPERIMENTAL
Intervention: Proactive push translation strategies such as reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the intervention
Number of subjects: 0
Study: 11332926

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg elemental)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zinc plus Vitamin A
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (neither zinc nor vitamin A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 96
Study: 9110923

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg once daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg once daily)
Number of subjects: 23
Study: 7962886

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Relaxation training (RT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Minimal-contact control (MCC)
Number of subjects: 64
Study: 3117082

Group type: EXPERIMENTAL
Intervention: isoflurane and nitrous oxide
Number of subjects: 21

Group type: COMPARATOR
Intervention: halothane and nitrous oxide
Number of subjects: 21
Study: 30689621

Group type: EXPERIMENTAL
Intervention: Early surgery (vitrectomy within 4 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Delayed surgery (vitrectomy between 10-14 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 53
Study: 31248425

Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 0
Study: 28202033

Group type: EXPERIMENTAL
Intervention: Stepwise lactate kinetics-oriented hemodynamic therapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: ScvO2-oriented hemodynamic therapy
Number of subjects: 360
Study: 26387028

Group type: EXPERIMENTAL
Intervention: Loading-dose rosuvastatin 20 mg 12 hours prior to PCI, with a second dose just before PCI.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group treated with standard method according to ACC/AHA guidelines in UAP/NSTEMI 2007.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Loading-dose rosuvastatin therapy.
Number of subjects: 126
Study: 23261174

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simvastatin/ezetimibe 10/10 mg
Number of subjects: 100
Study: 21627526

Group type: EXPERIMENTAL
Intervention: Vaccine B (2 mL doses, n = 12)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Experimental bacterin (n = 12)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vaccine A (5 mL doses, n = 13)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham vaccine (n = 14)
Number of subjects: 51
Study: 19378885

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC) starting 30 minutes before and continuing 10 minutes after an invasive procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 50
Study: 17225048

Group type: EXPERIMENTAL
Intervention: Groups A, B, C (iodine dose 450-600 mg/kg, injection duration 30 s)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group D (iodine dose 450 mg/kg, injection duration 25 s)
Number of subjects: 20
Study: 15321810

Group type: EXPERIMENTAL
Intervention: High-soy diet (104 +/- 24 mg total isoflavones/d)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low-soy diet (0.54 +/- 0.58 mg total isoflavones/d)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High-soy diet
Number of subjects: 76
Study: 11463411

Group type: EXPERIMENTAL
Intervention: Vasopressin 40 U
Number of subjects: 200

Group type: COMPARATOR
Intervention: Epinephrine 1 mg
Number of subjects: 200
Study: 9512230

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) in patients with previous failed fertilization or low fertilization rate
Number of subjects: 284

Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI) in patients with primary male factor
Number of subjects: 284
Study: 7518728

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months in males
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months in females
Number of subjects: 21
Study: 3177228

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 to 180 mg twice daily, mean dose 307 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31785275

Group type: EXPERIMENTAL
Intervention: Endoscopic clipping closure
Number of subjects: 155

Group type: COMPARATOR
Intervention: Nonclosure
Number of subjects: 155
Study: 30499685

Group type: EXPERIMENTAL
Intervention: Circulating bone-specific alkaline phosphatase (BALP) levels
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein, dialysis vintage, and BALP
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: BALP levels
Number of subjects: 156
Study: 26887576

Group type: EXPERIMENTAL
Intervention: Aqua-cycling (two 45-min sessions weekly for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 26259989

Group type: EXPERIMENTAL
Intervention: Ustekinumab half-standard dosing (HSD)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ustekinumab standard dosing (SD)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110
Study: 23786937

Group type: EXPERIMENTAL
Intervention: Occlusal splints for 1 month
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (non-occluding palatal) splints
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Occlusal splints
Number of subjects: 36
Study: 21178616

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional-dose therapy (including bortezomib and immune-modulatory drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring using NT-proBNP, cTn, and FLC
Number of subjects: 0
Study: 19032132

Group type: EXPERIMENTAL
Intervention: Oxycodone PR/Naloxone PR
Number of subjects: 322

Group type: COMPARATOR
Intervention: Oxycodone PR
Number of subjects: 322
Study: 17220048

Group type: EXPERIMENTAL
Intervention: Test formulation of losartan (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of losartan (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 14694935

Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis (5 monthly intramuscular injections at 15 mg/kg)
Number of subjects: 0
Study: 9428859

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 45
Study: 8595788

Group type: COMPARATOR
Intervention: Tiagabine (TGB) hydrochloride as add-on therapy
Number of subjects: 2261

Group type: COMPARATOR
Intervention: Tiagabine (TGB) hydrochloride
Number of subjects: 2261
Study: 2529893

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 50
Study: 1107360

Group type: EXPERIMENTAL
Intervention: Loxapine succinate (40-80 mg daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Trifluoperazine (20-50 mg daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Loxapine succinate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 43
Study: 29982805

Group type: EXPERIMENTAL
Intervention: depatuziuzumab mafodotin (0.5-1.5 mg/kg) + temozolomide (150-200 mg/m2)
Number of subjects: 60
Study: 29138547

Group type: EXPERIMENTAL
Intervention: 5 μg tiotropium for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 150 μg indacaterol for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination therapy of tiotropium and indacaterol for 4 weeks
Number of subjects: 30
Study: 23998376

Group type: EXPERIMENTAL
Intervention: SAAF-T intervention
Number of subjects: 473
Study: 21447368

Group type: EXPERIMENTAL
Intervention: Laser irradiation (L)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fluoride (AmF/NaF gel) application (F)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Laser prior to fluoride (LF)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fluoride prior to laser (FL)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non‐treated control (C)
Number of subjects: 130
Study: 19416526

Group type: EXPERIMENTAL
Intervention: LPS (4 ng/kg) administered intravenously
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RWJ-67657 (p38 MAP kinase inhibitor) administered 30 minutes before LPS infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Septic patients (21 patients)
Number of subjects: 22
Study: 17156221

Group type: EXPERIMENTAL
Intervention: rocuronium
Number of subjects: 338

Group type: COMPARATOR
Intervention: cisatracurium
Number of subjects: 338
Study: 15124707

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stem cell allografting from alternative donors
Number of subjects: 0
Study: 11435335

Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 9681666

Group type: COMPARATOR
Intervention: Citalopram (40 mg oral or intravenous for healthy subjects; 20 mg oral for patients with renal insufficiency or hepatic cirrhosis)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg oral for patients with hepatic cirrhosis)
Number of subjects: 3
Study: 8042927

Group type: EXPERIMENTAL
Intervention: Hydergine (ergoloid mesylates)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 1955122

Group type: EXPERIMENTAL
Intervention: Cisapride (0.3 mg/kg PO t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study: 772425

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 54
Study: 31734696

Group type: EXPERIMENTAL
Intervention: CMV intravenous immunoglobulin (IVIG)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no IVIG)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CMV IVIG
Number of subjects: 61
Study: 30597112

Group type: EXPERIMENTAL
Intervention: lemborexant 2.5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lemborexant 10 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: zopiclone 7.5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 28544807

Group type: EXPERIMENTAL
Intervention: Teriparatide for 1 year
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 24
Study: 25378034

Group type: EXPERIMENTAL
Intervention: 5% oral glucose solution
Number of subjects: 80
Study: 23628109

Group type: EXPERIMENTAL
Intervention: Embryo culture in an atmosphere of 5.5% CO2, 6% O2, and 88.5% N2
Number of subjects: 1125

Group type: COMPARATOR
Intervention: 5.5% CO2 in air
Number of subjects: 1125
Study: 21305270

Group type: EXPERIMENTAL
Intervention: ROSU 10 mg/day starting 5 days before the infusion of ZOL for a total period of 11 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: No ROSU treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ROSU 10 mg/day
Number of subjects: 28
Study: 19824553

Group type: EXPERIMENTAL
Intervention: Oral-B Exceed toothbrush
Number of subjects: 41

Group type: COMPARATOR
Intervention: Asian Colgate 360 degrees toothbrush
Number of subjects: 41
Study: 16886588

Group type: EXPERIMENTAL
Intervention: Children with DM1
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study: 15999214

Group type: EXPERIMENTAL
Intervention: n-butyl-(2)-cyanoacrylate (NBCA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: n-butyl-(2)-cyanoacrylate + methacryloxysulfolane (NBCA-MS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Younger than 18 years
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Older than 18 years
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patients with vessel wall perforation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patients without vessel wall perforation
Number of subjects: 64
Study: 14572489

Group type: EXPERIMENTAL
Intervention: Oligon Vantex silver central venous catheter (CVC)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard polyurethane central venous catheter (CVC)
Number of subjects: 206
Study: 10624955

Group type: EXPERIMENTAL
Intervention: Stereoscopic phenomena
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual system mechanisms
Number of subjects: 0
Study: 7717631

Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 82
Study: 2115503

Group type: EXPERIMENTAL
Intervention: Prophylaxis regimen consisting of polymyxin E, tobramycin, and amphotericin B
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200